SCHEMBL4226994

SCHEMBL4226994

CCOc1cc(NC(=O)NC(CC)CC)ccc1Oc1ccc(C(N)=O)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.46
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
PARP10 Q53GL7 3/20 0.39
PARP14 Q460N5 1/20 0.39
MCHR1 Q99705 1/20 0.39
P2RX3 P56373 1/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PARP15 Q460N3 1/20 0.38
C5 P01031 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4226997 0.88 PKM (0.47) PKMALDH1A1TDP1KMT2ATAS1R3
SCHEMBL4236662 0.85 PKM (0.50) PKMALDH1A1TDP1MEN1KMT2A
SCHEMBL4683259 0.85 PKM (0.49) PKMALDH1A1MEN1KMT2ATAS1R3
SCHEMBL4686265 0.84 EPHX1 (0.46) ALDH1A1MEN1KMT2AMCHR1
SCHEMBL4236665 0.83 PKM (0.52) PKMALDH1A1TDP1MEN1KMT2A
SCHEMBL4229403 0.82 PKM (0.40) PKMALDH1A1TDP1KMT2ATAS1R3
SCHEMBL4233270 0.81 PKM (0.52) PKMALDH1A1TDP1MEN1KMT2A
SCHEMBL4237924 0.81 PKM (0.55) PKMALDH1A1TDP1MEN1KMT2A
SCHEMBL4240206 0.79 PKM (0.60) PKMTAS1R3TAS1R1PARP10PARP14
SCHEMBL4238811 0.78 PKM (0.50) PKMALDH1A1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885ALDH1A1 4542/4885TDP1 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.